News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,791 Results
Type
Article (40967)
Company Profile (267)
Press Release (681547)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (204690)
Career Advice (2025)
Deals (35537)
Drug Delivery (114)
Drug Development (81393)
Employer Resources (173)
FDA (16419)
Job Trends (14947)
News (346438)
Policy (32734)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2573)
Accelerated approval (35)
Adcomms (24)
Allergies (149)
Alliances (49578)
ALS (174)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (321)
Approvals (16698)
Artificial intelligence (531)
Autoimmune disease (162)
Automation (43)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (194)
Biotechnology (174)
Bladder cancer (162)
Brain cancer (58)
Breast cancer (649)
Cancer (4918)
Cardiovascular disease (408)
Career advice (1710)
Career pathing (36)
CAR-T (285)
CDC (48)
Celiac Disease (2)
Cell therapy (753)
Cervical cancer (37)
Clinical research (69681)
Collaboration (1740)
Company closure (4)
Compensation (1182)
Complete response letters (57)
COVID-19 (2715)
CRISPR (94)
C-suite (874)
Cystic fibrosis (143)
Data (6373)
Decentralized trials (2)
Denatured (25)
Depression (136)
Diabetes (507)
Diagnostics (6724)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (257)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (236)
Earnings (90333)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117605)
Executive appointments (988)
FDA (19605)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1499)
Gene editing (201)
Generative AI (44)
Gene therapy (605)
GLP-1 (974)
Government (4670)
Grass and pollen (6)
Guidances (385)
Healthcare (18884)
HIV (62)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (63)
Indications (125)
Infectious disease (2996)
Inflammatory bowel disease (195)
Inflation Reduction Act (14)
Influenza (120)
Intellectual property (256)
Interviews (316)
IPO (16645)
IRA (50)
Job creations (3643)
Job search strategy (1428)
JPM (57)
Kidney cancer (17)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7951)
Liver cancer (92)
Longevity (17)
Lung cancer (663)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (822)
MASH (165)
Medical device (13788)
Medtech (13848)
Mergers & acquisitions (19971)
Metabolic disorders (1287)
mRNA (158)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (326)
Neuropsychiatric disorders (89)
Neuroscience (2943)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (68)
Obesity (606)
Opinion (264)
Ovarian cancer (168)
Pain (202)
Pancreatic cancer (234)
Parkinson's disease (288)
Partnered (33)
Patents (512)
Patient recruitment (510)
Peanut (59)
People (58952)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21724)
Phase 2 (30669)
Phase 3 (22844)
Pipeline (5626)
Policy (290)
Postmarket research (2564)
Preclinical (9211)
Press Release (64)
Prostate cancer (250)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (866)
Real estate (5956)
Recruiting (70)
Regulatory (24599)
Reports (53)
Research institute (2393)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (248)
Series B (191)
Service/supplier (11)
Sickle cell disease (100)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3617)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (1014)
Venture capital (89)
Weight loss (386)
Women's health (96)
Worklife (18)
Date
Today (176)
Last 7 days (762)
Last 30 days (2676)
Last 365 days (29996)
2026 (4507)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46540)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37553)
2014 (31321)
2013 (26349)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (86)
Alaska (7)
Arizona (313)
Arkansas (13)
Asia (39258)
Australia (6420)
California (11525)
Canada (3336)
China (1113)
Colorado (483)
Connecticut (487)
Delaware (341)
Europe (84680)
Florida (1729)
Georgia (364)
Hawaii (3)
Idaho (61)
Illinois (884)
India (70)
Indiana (533)
Iowa (22)
Japan (439)
Kansas (127)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1405)
Massachusetts (8239)
Michigan (331)
Minnesota (632)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (80)
New Jersey (3057)
New Mexico (28)
New York (3032)
North Carolina (1475)
North Dakota (8)
Northern California (5657)
Ohio (343)
Oklahoma (21)
Oregon (41)
Pennsylvania (2330)
Puerto Rico (24)
Rhode Island (49)
South America (1108)
South Carolina (68)
South Dakota (1)
Southern California (4489)
Tennessee (178)
Texas (1773)
United States (40805)
Utah (348)
Vermont (1)
Virginia (268)
Washington D.C. (81)
Washington State (932)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
722,791 Results for "organovo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
February 26, 2025
·
2 min read
Biotech Beach
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. announced the pricing of a public offering consisting of 6,562,500 shares of common stock and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80.
May 8, 2024
·
4 min read
Press Releases
Organovo Announces Reverse Stock Split
March 20, 2025
·
3 min read
Press Releases
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
April 3, 2025
·
4 min read
Biotech Beach
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo Holdings, Inc. announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024.
May 14, 2024
·
2 min read
Press Releases
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
March 26, 2025
·
2 min read
Press Releases
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
March 7, 2025
·
2 min read
Press Releases
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
January 6, 2025
·
4 min read
Biotech Beach
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Organovo Holdings, Inc. announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024.
November 8, 2023
·
4 min read
Drug Development
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Organovo Holdings, Inc. today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024.
December 6, 2023
·
4 min read
1 of 72,280
Next
